Dynamic single-cell mapping unveils Epstein‒Barr virus-imprinted T-cell exhaustion and on-treatment response
Open Access
- 21 September 2023
- journal article
- research article
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-13
Abstract
Epstein‒Barr virus (EBV)-associated gastric cancer (GC) manifests an intriguing immunotherapy response. However, the cellular basis for EBV-imprinted tumour immunity and on-treatment response remains undefined. This study aimed to finely characterize the dynamic tumour immune contexture of human EBV (+) GC treated with immunochemotherapy by longitudinal scRNA-seq and paired scTCR/BCR-seq. EBV (+) GC exhibits an inflamed-immune phenotype with increased T-cell and B-cell infiltration. Immunochemotherapy triggers clonal revival and reinvigoration of effector T cells which step to determine treatment response. Typically, an antigen-specific ISG-15+CD8+ T-cell population is highly enriched in EBV (+) GC patients, which represents a transitory exhaustion state. Importantly, baseline intratumoural ISG-15+CD8+ T cells predict immunotherapy responsiveness among GC patients. Re-emerged clonotypes of pre-existing ISG-15+CD8+ T cells could be found after treatment, which gives rise to a CXCL13-expressing effector population in responsive EBV (+) tumours. However, LAG-3 retention may render the ISG-15+CD8+ T cells into a terminal exhaustion state in non-responsive EBV (+) tumours. In accordance, anti-LAG-3 therapy could effectively reduce tumour burden in refractory EBV (+) GC patients. Our results delineate a distinct implication of EBV-imprinted on-treatment T-cell immunity in GC, which could be leveraged to optimize the rational design of precision immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82173128, 82073377, 81772587, 82172861)
- Natural Science Foundation of Guangdong Province (2021A1515012439, 2021A1515011743)
This publication has 42 references indexed in Scilit:
- Clinical blockade of PD1 and LAG3 — potential mechanisms of actionNature Reviews Immunology, 2014
- Comprehensive molecular characterization of gastric adenocarcinomaNature, 2014
- Interferon-Stimulated Genes: A Complex Web of Host DefensesAnnual Review of Immunology, 2014
- Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of MelanomaThe Journal of Immunology, 2013
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancerProceedings of the National Academy of Sciences, 2010
- On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infectionInternational Immunology, 2009
- CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus–transformed B cellsBlood, 2009
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infectionNature Immunology, 2008
- LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systemsJournal of Clinical Investigation, 2007